Transcatheter Closure of Atrial Septal Defect with Carag Bioresorbable Septal Occluder™: First-in-Child Experience with 12-MonthFollow-Up

Figure 2

Short-axis view showing the visibility of the implanted CBSO occluder during implantation (on TOE), at 6 months follow-up (on TTE), and at 12 months follow-up (on TTE). The site of measurement of a septal thickness (yellow line) is shown in the image on the right. (a) Periprocedural (TOE), (b) at 6 months follow-up (TTE), and (c) at 12 months follow-up (TTE).

(a)

(b)

(c)